Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

MLA

Elias Jabbour, et al. “Mini-Hyper-CVD plus Inotuzumab Ozogamicin, with or without Blinatumomab, in the Subgroup of Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphocytic Leukaemia: Long-Term Results of an Open-Label Phase 2 Trial.” The Lancet Haematology, May 2023. EBSCOhost, https://doi.org/10.1016/s2352-3026(23)00073-x.

APA

Elias Jabbour, Nicholas J Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D DiNardo, Naveen Pemmaraju, William Wierda, Guillermo Garcia-Manero, Guillermo Montalban Bravo, Koji Sasaki, Tapan M Kadia, Joseph Khoury, Sa A Wang, Fadi G Haddad, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, & Hagop M Kantarjian. (2023). Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(23)00073-x

Chicago

Elias Jabbour, Nicholas J Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D DiNardo, et al. 2023. “Mini-Hyper-CVD plus Inotuzumab Ozogamicin, with or without Blinatumomab, in the Subgroup of Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphocytic Leukaemia: Long-Term Results of an Open-Label Phase 2 Trial.” The Lancet Haematology, May. doi:10.1016/s2352-3026(23)00073-x.